glp-1 in heart failure GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes

📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no

20.62

★★★★☆4.8 (126)

Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes

21.61

★★★★★4.9 (98)

Stopping GLP-1 drugs can quickly erase cardiovascular benefits – WashU Medicine

20.56

★★★★★5.0 (157)

GLP-1 Receptor Agonists in Heart Failure Management

24.20

★★★★★4.7 (84)

GLP-1 medications like Ozempic, Wegovy and Mounjaro are changing diabetes and weight management, but they aren't recommended during pregnancy or while nursing. The current recommendation is to stop before conception and discuss

22.61

★★★★★4.9 (203)

Navigating GLP-1 and Pregnancy: Insights, Safety, and Postpartum Considerations

27.20

★★★★★5.0 (176)

GLP-1s (Weight loss injections) AND PREGNANCY 💉GLP-1 agonists include medications such as tirzepatide and semaglutide which may be better known by their different brand names (such as Wegovy and Mounjaro). They are

23.17

★★★★★4.8 (132)